Is Selinisol a targeted drug or a chemotherapy drug? What is its mechanism of action?
Selinexor is a new type of oral anti-cancer drug. It is different from traditional chemotherapy drugs and is not a common targeted drug. It is a selective nuclear export inhibitor (SINE). It inhibits the function of XPO1 (Exportin 1) protein and prevents tumor suppressor proteins from being transported from the nucleus to the cytoplasm, thereby enhancing anti-cancer signals in cancer cells and inducing cancer cell apoptosis. This unique mechanism of action allows selinesol to exhibit good anti-tumor activity in the treatment of a variety of hematological tumors.

Currently, selinesol is mainly used to treat relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Unlike traditional chemotherapy, it does not work by directly killing rapidly dividing cells, but restores tumor suppressor signals inside cancer cells, causing them to lose their ability to grow and eventually undergo apoptosis. At the same time, it is different from targeted drugs because it does not target a specific gene mutation, but inhibits cancer progression by affecting the nuclear export mechanism of tumor cells. Therefore, selinesol is considered a new anti-cancer drug between targeted therapy and chemotherapy, with unique therapeutic value.
In clinical studies, Selinisol combined with dexamethasone (Dexamethasone) has shown good efficacy in patients with relapsed and refractory multiple myeloma, especially in patients who have received multiple lines of treatment and are resistant, and can still provide a certain survival benefit. The adverse reactions mainly include nausea, vomiting, fatigue, decreased appetite, thrombocytopenia, etc., but most of them can be managed through symptomatic treatment. Since the side effects of this drug are relatively strong, patients need to closely monitor blood routine, liver and kidney function and other indicators when taking it, and adjust the dose reasonably under the guidance of a doctor.
Reference materials:https://www.selincro.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)